A prospective, cohort study to evaluate fourth dose of BNT162b2 for protection against infection associated with SARS-CoV-2, hospitalizations, and deaths during the omicron surge in long-term care facility (LTCF) residents
Latest Information Update: 29 Jun 2022
At a glance
- Drugs Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
Most Recent Events
- 29 Jun 2022 New trial record
- 23 Jun 2022 Results published in the JAMA Internal Medicine